Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aripiprazole plus escitalopram for cognitive function in major depressive disorder
ChiCTR1900028541Phase 4Not yet recruiting
- Sponsor
- Shandong Mental Health Center
- Start
- Jan 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of aripiprazole and escitalopram in major depressive disorder (MDD) (2 arms), sponsored by Shandong Mental Health Center. Primary endpoints: Serum prolactin levels at week 8, Hamilton Depression Scale at week 8 and 9 more. Planned start Jan 2020; status: not yet recruiting.
02
Drugs
aripiprazoleescitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ChiCTR1900028541.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1900028541.